Denise Scots-Knight

Denise Scots-Knight currently serves as a Non Executive Board Member at Elanco and as the Chief Executive Officer of Mereo BioPharma. With a robust background in the biotech and pharmaceutical industries, Denise held the position of Managing Partner at Phase4 Partners and Managing Director at Nomura Phase4 Ventures. Additionally, Denise contributed to the British Heart Foundation as a Trustee and Member of the Council. Previous roles include Investment Manager at Rothschild Asset Management. Denise's academic credentials include a PhD in Biochemistry from the University of Birmingham and a Fulbright Scholarship in Biochemistry from the University of California, Berkeley.